{"id":64560,"date":"2026-07-13T19:30:00","date_gmt":"2026-07-13T12:30:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=64560"},"modified":"2026-07-13T19:30:00","modified_gmt":"2026-07-13T12:30:00","slug":"servier-completes-the-acquisition-of-edgewise-therapeutics-muscular-dystrophy-business","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=64560","title":{"rendered":"Servier completes the acquisition of Edgewise Therapeutics&#8217; Muscular Dystrophy Business"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2766991\/Servier_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><b>Acquisition supports\u00a0Servier&#8217;s\u00a0strategic\u00a0ambition in rare neurology\u00a0with\u00a0sevasemten, a\u00a0late-stage\u00a0investigational\u00a0treatment for\u00a0Becker and Duchenne\u00a0muscular\u00a0dystrophies.\u00a0<\/b>\u00a0\n<\/li>\n<li><b>The\u00a0acquired\u00a0asset\u00a0and\u00a0expert\u00a0team\u00a0strengthen\u00a0Servier&#8217;s\u00a0commitment\u00a0to innovate for patients with high unmet medical needs.\u00a0<\/b>\u00a0<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\">SURESNES, France<\/span>, <span class=\"legendSpanClass\">July 13, 2026<\/span> \/PRNewswire\/ &#8212;\u00a0Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc. (Nasdaq: EWTX),\u00a0for\u00a0up to\u00a0$2.65 billion,\u00a0including upfront payment of $1.55 billion as well as up to $1.1 billion in regulatory and commercial milestone payments. This announcement follows regulatory clearance and customary closing conditions.\u00a0<\/p>\n<p>The\u00a0acquisition\u00a0significantly advances Servier&#8217;s\u00a0rare\u00a0neurology\u00a0pipeline with a late-stage asset,\u00a0sevasemten,\u00a0currently being investigated in a pivotal cohort in Becker muscular dystrophy\u00a0(BMD), and in phase 2 in Duchenne muscular dystrophy\u00a0(DMD). It also provides Servier with additional capabilities by integrating Edgewise Therapeutics&#8217; expertise to advance the development of sevasemten.\u00a0<\/p>\n<p>Sevasemten is an orally administered potential first-in-class fast skeletal myosin inhibitor designed to preserve and protect unstable muscle against contraction-induced damage in individuals living with rare muscular dystrophy.\u00a0BMD\u00a0is a\u00a0rare,\u00a0X-linked\u00a0genetic disorder that causes progressive muscle loss, with\u00a0currently no approved treatment for patients.\u00a0The\u00a0loss of\u00a0muscle\u00a0function\u00a0is irreversible and impacts patients&#8217; abilities to perform everyday activities like walking.\u00a0DMD\u00a0is a\u00a0more\u00a0severe, recessive\u00a0X-linked\u00a0genetic, degenerative muscle disorder beginning at birth that causes patients to lose their walking ability by their early teens. It is the most common type of muscular dystrophy with a median life expectancy of around\u00a030\u202fyears.\u00a0<\/p>\n<p>&#8220;Delivering precision therapies to people with\u00a0rare\u00a0and devastating conditions is at the heart of Servier&#8217;s mission.\u00a0The combination of\u00a0Edgewise&#8217;s\u00a0expertise\u00a0in muscular dystrophy\u00a0with\u00a0Servier&#8217;s\u00a0global\u00a0capabilities\u00a0is a major step forward\u00a0to\u00a0accelerate the development of\u00a0innovative treatments\u00a0for\u00a0people\u00a0living with Becker and Duchenne&#8221;,\u00a0said\u00a0<b>Olivier Laureau, President of Servier. <\/b>&#8220;This acquisition is a strategic milestone in achieving\u00a0our Servier 2030 ambition\u00a0in rare neurology.&#8221;\u00a0<\/p>\n<p>&#8220;Servier&#8217;s\u00a0strong\u00a0commitment to patients, growing focus\u00a0on\u00a0rare\u00a0neurology, and established global capabilities position them as the optimal partner to advance\u00a0the\u00a0muscular dystrophy\u00a0business&#8221;,\u00a0said\u00a0<b>Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise Therapeutics.\u00a0<\/b><\/p>\n<p><b>Contacts<\/b><br \/>Servier Group, Olympe Muller<br \/><a href=\"mailto:olympe.muller@servier.com\" target=\"_blank\" rel=\"nofollow\">olympe.muller@servier.com<\/a><\/p>\n<p>PDF &#8211; <a href=\"https:\/\/mma.prnewswire.com\/media\/3005524\/PDF.pdf\" target=\"_blank\" rel=\"nofollow\">https:\/\/mma.prnewswire.com\/media\/3005524\/PDF.pdf<\/a><\/p>\n<p>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2766991\/Servier_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><b>Acquisition supports\u00a0Servier&#8217;s\u00a0strategic\u00a0ambition in rare neurology\u00a0with\u00a0sevasemten, a\u00a0late-stage\u00a0investigational\u00a0treatment for\u00a0Becker and Duchenne\u00a0muscular\u00a0dystrophies.\u00a0<\/b>\u00a0\n<\/li>\n<li><b>The\u00a0acquired\u00a0asset\u00a0and\u00a0expert\u00a0team\u00a0strengthen\u00a0Servier&#8217;s\u00a0commitment\u00a0to innovate for patients with high unmet medical needs.\u00a0<\/b>\u00a0<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\">SURESNES, France<\/span>, <span class=\"legendSpanClass\">July 13, 2026<\/span> \/PRNewswire\/ &#8212;\u00a0Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc. (Nasdaq: EWTX),\u00a0for\u00a0up to\u00a0$2.65 billion,\u00a0including upfront payment of $1.55 billion as well as up to $1.1 billion in regulatory and commercial milestone payments. This announcement follows regulatory clearance and customary closing conditions.\u00a0<\/p>\n<p>The\u00a0acquisition\u00a0significantly advances Servier&#8217;s\u00a0rare\u00a0neurology\u00a0pipeline with a late-stage asset,\u00a0sevasemten,\u00a0currently being investigated in a pivotal cohort in Becker muscular dystrophy\u00a0(BMD), and in phase 2 in Duchenne muscular dystrophy\u00a0(DMD). It also provides Servier with additional capabilities by integrating Edgewise Therapeutics&#8217; expertise to advance the development of sevasemten.\u00a0<\/p>\n<p>Sevasemten is an orally administered potential first-in-class fast skeletal myosin inhibitor designed to preserve and protect unstable muscle against contraction-induced damage in individuals living with rare muscular dystrophy.\u00a0BMD\u00a0is a\u00a0rare,\u00a0X-linked\u00a0genetic disorder that causes progressive muscle loss, with\u00a0currently no approved treatment for patients.\u00a0The\u00a0loss of\u00a0muscle\u00a0function\u00a0is irreversible and impacts patients&#8217; abilities to perform everyday activities like walking.\u00a0DMD\u00a0is a\u00a0more\u00a0severe, recessive\u00a0X-linked\u00a0genetic, degenerative muscle disorder beginning at birth that causes patients to lose their walking ability by their early teens. It is the most common type of muscular dystrophy with a median life expectancy of around\u00a030\u202fyears.\u00a0<\/p>\n<p>&#8220;Delivering precision therapies to people with\u00a0rare\u00a0and devastating conditions is at the heart of Servier&#8217;s mission.\u00a0The combination of\u00a0Edgewise&#8217;s\u00a0expertise\u00a0in muscular dystrophy\u00a0with\u00a0Servier&#8217;s\u00a0global\u00a0capabilities\u00a0is a major step forward\u00a0to\u00a0accelerate the development of\u00a0innovative treatments\u00a0for\u00a0people\u00a0living with Becker and Duchenne&#8221;,\u00a0said\u00a0<b>Olivier Laureau, President of Servier. <\/b>&#8220;This acquisition is a strategic milestone in achieving\u00a0our Servier 2030 ambition\u00a0in rare neurology.&#8221;\u00a0<\/p>\n<p>&#8220;Servier&#8217;s\u00a0strong\u00a0commitment to patients, growing focus\u00a0on\u00a0rare\u00a0neurology, and established global capabilities position them as the optimal partner to advance\u00a0the\u00a0muscular dystrophy\u00a0business&#8221;,\u00a0said\u00a0<b>Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise Therapeutics.\u00a0<\/b><\/p>\n<p><b>Contacts<\/b><br \/>Servier Group, Olympe Muller<br \/><a href=\"mailto:olympe.muller@servier.com\" target=\"_blank\" rel=\"nofollow\">olympe.muller@servier.com<\/a><\/p>\n<p>PDF &#8211; <a href=\"https:\/\/mma.prnewswire.com\/media\/3005524\/PDF.pdf\" target=\"_blank\" rel=\"nofollow\">https:\/\/mma.prnewswire.com\/media\/3005524\/PDF.pdf<\/a><\/p>\n<p>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-64560","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/64560","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64560"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/64560\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64560"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64560"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64560"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}